Innoviva Revenue 2010-2023 | INVA

Innoviva revenue from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Innoviva Annual Revenue
(Millions of US $)
2023 $310
2022 $331
2021 $392
2020 $337
2019 $261
2018 $261
2017 $217
2016 $134
2015 $54
2014 $8
2013 $5
2012 $6
2011 $25
2010 $24
2009 $24
Innoviva Quarterly Revenue
(Millions of US $)
2023-12-31 $86
2023-09-30 $67
2023-06-30 $81
2023-03-31 $76
2022-12-31 $66
2022-09-30 $67
2022-06-30 $108
2022-03-31 $90
2021-12-31 $108
2021-09-30 $98
2021-06-30 $101
2021-03-31 $86
2020-12-31 $90
2020-09-30 $89
2020-06-30 $79
2020-03-31 $79
2019-12-31 $76
2019-09-30 $66
2019-06-30 $64
2019-03-31 $55
2018-12-31 $80
2018-09-30 $62
2018-06-30 $67
2018-03-31 $52
2017-12-31 $70
2017-09-30 $49
2017-06-30 $59
2017-03-31 $40
2016-12-31 $44
2016-09-30 $33
2016-06-30 $32
2016-03-31 $24
2015-12-31 $23
2015-09-30 $14
2015-06-30 $11
2015-03-31 $7
2014-12-31 $7
2014-09-30 $1
2014-06-30 $1
2014-03-31 $-1
2013-12-31 $1
2013-09-30 $0
2013-06-30 $1
2013-03-31 $1
2012-12-31 $6
2012-09-30 $1
2012-06-30 $1
2012-03-31 $127
2011-12-31 $5
2011-09-30 $6
2011-06-30 $6
2011-03-31 $6
2010-12-31 $7
2010-09-30 $5
2010-06-30 $6
2010-03-31 $6
2009-12-31 $4
2009-09-30 $6
2009-06-30 $5
2009-03-31 $10
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.930B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $721.736B 120.19
Novo Nordisk (NVO) Denmark $562.737B 46.36
Johnson & Johnson (JNJ) United States $358.552B 14.27
Merck (MRK) United States $319.493B 84.10
AbbVie (ABBV) United States $296.619B 15.08
AstraZeneca (AZN) United Kingdom $215.324B 19.08
Novartis AG (NVS) Switzerland $199.963B 13.85
Pfizer (PFE) United States $149.151B 14.39
Sanofi (SNY) $117.880B 10.61